ARIA Sent £50m of UK Public Funds to US Firms

The revelation puts a spotlight on whether ARIA, established under the Advanced Research and Invention Agency Act 2022 with an initial budget of £800m, is channelling sufficient capital toward domestic research. For UK founders building deep-tech and science-led businesses, the agency's allocation pattern carries practical implications about where non-dilutive public funding actually lands.

Where the £50m went

ARIA has committed approximately £50m to US-based technology companies and venture capital projects, as first reported by the Guardian. The sum represents a material share of the funds ARIA has deployed so far from its £800m multi-year budget.

The agency was conceived by Dominic Cummings, the former chief adviser to Boris Johnson, and was explicitly modelled on the US Defense Advanced Research Projects Agency (DARPA). Its stated purpose, in the words of the government at the time of its creation, was to "restore Britain's place as a scientific superpower," according to a 2021 article by the then prime minister published in the Daily Telegraph.

ARIA operates with minimal bureaucratic oversight by design. The 2022 Act granted it exemptions from Freedom of Information requests, a deliberate structural choice intended to let programme directors back unconventional, high-risk research without the friction that typically accompanies public spending. That same freedom, however, makes it harder for external observers, including Parliament, to scrutinise where the money goes.

The Guardian's reporting did not provide a full breakdown of individual recipients. What is clear is that a significant tranche of taxpayer-funded capital has crossed the Atlantic rather than staying within the UK research ecosystem.

What ARIA's mandate actually requires

ARIA's legislative mandate does not explicitly restrict spending to UK-domiciled entities. The 2022 Act gives the agency broad latitude to fund research it judges to have "the potential to produce significant benefits" through scientific discovery and invention. Geography is not a binding constraint in the statute.

That breadth was intentional. Proponents argued during the Act's passage that confining ARIA to domestic recipients would undermine its ability to assemble the best research teams globally. Science does not respect borders, and DARPA itself routinely funds international collaborators.

Yet the political context has shifted. UK gross domestic expenditure on research and development stood at £44.4bn in 2022, according to Office for National Statistics data. The government's target of spending 2.4% of GDP on R&D by 2027 remains unmet. Every public research pound is under scrutiny, and the industrial strategy review currently under way has sharpened the focus on domestic returns from public investment.

The tension is straightforward. ARIA's architects wanted an agency unshackled from geographic parochialism. Critics now ask whether an agency funded entirely by UK taxpayers should be sending a notable portion of its committed capital to firms headquartered in the United States, particularly when domestic deep-tech ventures report persistent difficulty accessing early-stage, non-dilutive funding.

The funding gap for UK deep-tech ventures

The UK deep-tech sector has long operated in a capital environment that is generous by European standards but thin compared with the US. Innovate UK, the country's main public innovation agency, disbursed approximately £1.1bn in grants during the 2023-24 financial year, according to its annual report. The British Business Bank supports venture lending and co-investment. University spin-outs can tap proof-of-concept funds.

None of these routes, however, replicate what ARIA was supposed to offer: large, flexible, conviction-led grants for research too speculative for conventional funders. Programme directors at ARIA have the authority to write substantial cheques on the basis of scientific judgement alone, without the panel-review processes that govern most public grant-making.

For a UK-based quantum computing start-up or a synthetic biology spin-out from a Russell Group university, ARIA represented a new category of funder. The discovery that a material share of the agency's commitments has gone to US recipients recalibrates expectations. It does not close the door to domestic applicants, but it suggests that competition for ARIA capital is global, not national, and that the agency's programme directors are sourcing opportunities from networks that tilt toward the US venture and research ecosystem.

The structural lesson for UK operators is that ARIA behaves more like a sovereign deep-tech fund with a global mandate than a domestic grant body with a patriotic remit.

Founders seeking ARIA funding will need to engage directly with its programme directors and frame proposals in terms of scientific ambition rather than economic geography. The agency publishes its active programmes on its website, and each programme director sets their own thesis and call for proposals.

What operators should watch next

Several developments will determine whether ARIA's spending pattern shifts.

Parliamentary pressure. The Guardian's report is likely to prompt questions in the House of Commons. If the Science, Innovation and Technology Select Committee calls ARIA's leadership to give evidence, the agency may face informal pressure to demonstrate a stronger domestic pipeline, even if the statute does not require one.

Industrial strategy alignment. The government's ongoing industrial strategy review, led by the Department for Science, Innovation and Technology, could introduce new expectations for public R&D bodies. If ministers signal that agencies should prioritise domestic deployment, ARIA's programme directors may adjust their sourcing accordingly.

Budget trajectory. ARIA's £800m allocation covers its initial operating period. Future spending reviews will determine whether the agency receives additional capital. A perception that funds are flowing abroad rather than building UK capacity could weaken the Treasury's appetite to top up the budget.

Transparency measures. Although ARIA is exempt from FOI requests, it is not exempt from National Audit Office scrutiny. A formal NAO review of ARIA's spending could provide the detailed allocation data that the Guardian's report lacked, giving UK applicants a clearer picture of where the money has gone and what kinds of proposals succeed.

For UK deep-tech founders and research-led businesses, the immediate takeaway is operational, not political. ARIA exists, it has capital to deploy, and its mandate permits funding to flow anywhere. Winning a share of that capital requires understanding the agency's active programmes, building relationships with its programme directors, and presenting research that meets the bar of genuine scientific risk, the kind of work conventional funders will not touch.

The broader policy question, whether UK taxpayer money should primarily benefit UK-based science, is one for ministers and Parliament. But the answer will shape the funding landscape for years to come.